Diploma: a blue-chip set for strong growth
Diploma, whose niche products include seals and fasteners, serves an array of growth markets. Should you invest?
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
A small number of British firms have achieved sustained profitable growth using a combination of organic growth and bolt-on acquisitions, which are then developed much further. Diploma (LSE: DPLM) is a good example. I first recommended Diploma in MoneyWeek in April 2019, when the shares stood at 1,550p. That article pointed out that the share price had risen two-and-a-half times from 608p in autumn 2015 and suggested that there was plenty of potential for further growth.
This duly occurred: the recent share price is 4,140p, so the shares have risen almost threefold in just over five years, or nearly 22% per year with annual dividends on top of that. Diploma is a company in the FTSE 100 index with a market value of around £5.6 billion and 2023 turnover of £1.2 billion. The firm offers plenty of scope for further growth, with revenue up 52% between 2021 and 2023. Its three divisions all aim to achieve market-leading positions in their niches.
Diploma’s three arms are life sciences (comprising 17% of sales), seals (37%) and controls (45%). They all provide products coupled with services. These products and associated services are critical to customers, but of relatively low cost, so they are purchased from clients’ operating rather than capital budgets. Controls includes specialised fasteners (for aerospace, for instance) and adhesives; seals includes components and fittings for pneumatic pumps – both stock and custom-made, and often for mission-critical applications; life sciences includes technology-enabled products for surgery and endoscopy, along with diagnostic equipment for clinical laboratories and food safety testing.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Diploma's acquisitions drive profits
Diploma has a strong mergers-and-acquisitions (M&A) pipeline diversified by sector, size and geography. The firm made six acquisitions worth a total of £284 million in the first half of the year to 31 March 2024. This sum exceeded the total seen in the two full previous financial years. The largest purchase this year was America’s Peerless Aerospace Fasteners for £236 million. It will accelerate organic growth through product and geographical expansion and should add 8% to Diploma’s earnings per share (EPS) in the year after the takeover. The second-biggest acquisition was UK-based Plastics & Rubber Group Holdings (PAR) for £38 million. It will add scale to the seals-and-gaskets activities and deliver an additional 1% of EPS.
Both Peerless and PAR are founder-owned businesses with great records of organic growth and business models that match Diploma’s strategy of building high-quality businesses for sustainable organic growth. Diploma operates a decentralised business model that encourages entrepreneurship and focuses on core, scalable business lines that can be developed with organic growth supplemented by bolt-on acquisitions.
This strategy has driven the company’s profitable growth, with revenue more than doubling to £1.2 billion between 2020 and 2023, operating profit rising by 2.6 times over that period and the dividend climbing from 20.5p to 55.3p a share. Diploma serves a diversified set of growing markets, including clinical diagnostics, electrification, industrial automation, infrastructure, renewables, water management, energy and civil aerospace. This tempers the impact of a slowdown in any one market.
Diploma uses return on adjusted trading capital employed (ROATCE) as a key financial measure, which is more demanding than the usual gauge of profitability, return on capital employed (ROCE). ROATCE is the pre-tax return on total capital – fixed and working plus intangibles and goodwill, including goodwill previously written off against retained earnings. ROATCE, therefore, covers capital spent on acquisitions. Diploma’s average ROATCE for the past five years has been 19%.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.
Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development.
He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.
-
Should you buy an active ETF?ETFs are often mischaracterised as passive products, but they can be a convenient way to add active management to your portfolio
-
Power up your pension before 5 April – easy ways to save before the tax year endWith the end of the tax year looming, pension savers currently have a window to review and maximise what’s going into their retirement funds – we look at how
-
Three key winners from the AI boom and beyondJames Harries of the Trojan Global Income Fund picks three promising stocks that transcend the hype of the AI boom
-
RTX Corporation is a strong player in a growth marketRTX Corporation’s order backlog means investors can look forward to years of rising profits
-
Profit from MSCI – the backbone of financeAs an index provider, MSCI is a key part of the global financial system. Its shares look cheap
-
'AI is the real deal – it will change our world in more ways than we can imagine'Interview Rob Arnott of Research Affiliates talks to Andrew Van Sickle about the AI bubble, the impact of tariffs on inflation and the outlook for gold and China
-
Should investors join the rush for venture-capital trusts?Opinion Investors hoping to buy into venture-capital trusts before the end of the tax year may need to move quickly, says David Prosser
-
Food and drinks giants seek an image makeover – here's what they're doingThe global food and drink industry is having to change pace to retain its famous appeal for defensive investors. Who will be the winners?
-
Barings Emerging Europe trust bounces back from Russia woesBarings Emerging Europe trust has added the Middle East and Africa to its mandate, delivering a strong recovery, says Max King
-
How a dovish Federal Reserve could affect youTrump’s pick for the US Federal Reserve is not so much of a yes-man as his rival, but interest rates will still come down quickly, says Cris Sholto Heaton
